Published online before print August 18, 2003, doi: 10.1161/01.HYP.0000086521.95630.5A
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2003;42:239.)
© 2003 American Heart Association, Inc.
Scientific Contributions |
Diuretic Versus 
-Blocker as First-Step Antihypertensive Therapy
Final Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research GroupFrom the ALLHAT Collaborative Research Group.
Correspondence to Dr Michael H. Alderman, Albert Einstein College of Medicine, Department of Epidemiology and Population Health, 1300 Morris Park Ave, Bronx, NY 10461. E-mail alderman{at}aecom.yu.edu
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was a randomized, double-blind, active, controlled clinical trial conducted to determine whether newer antihypertensive agents, including doxazosin, an 
-blocker, differ from chlorthalidone, a diuretic, with respect to coronary heart disease (CHD) and other cardiovascular disease (CVD) events in hypertensive patients at high risk of CHD. In February 2000, the doxazosin treatment arm was discontinued, and findings through December 1999 were reported. This report includes an additional 9232 participant-years and 939 CVD events. At 623 clinical centers, patients (aged 
55 years) with hypertension and at least 1 other CHD risk factor were randomly assigned to either chlorthalidone or doxazosin. The primary outcome measure was the combined occurrence of fatal CHD or nonfatal myocardial infarction (MI), analyzed by intent to treat; prespecified secondary outcome measures included all-cause mortality, stroke, combined CHD (fatal CHD, nonfatal MI, hospitalized angina, and coronary revascularization), and combined CVD (combined CHD, stroke, angina treated outside the hospital, heart failure, and peripheral arterial disease). Mean follow-up was 3.2 years. There was no difference in primary outcome between the arms (relative risk [RR], 1.02; 95% confidence interval [CI], 0.92 to 1.15). All-cause mortality also did not differ (RR, 1.03; 95% CI, 0.94 to 1.13). However, the doxazosin arm compared with the chlorthalidone arm had a higher risk of stroke (RR, 1.26; 95% CI, 1.10 to 1.46) and combined CVD (RR 1.20; 95% CI, 1.13 to 1.27). These findings confirm the superiority of diuretic-based over -blocker–based antihypertensive treatment for the prevention of CVD.
Key Words: hypertension, detection and control • antihypertensive therapy • clinical trials • diuretics • adrenergic receptor blockers
This article has been cited by other articles:
 |
|
 |
|
  H. T. Ong Are Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Especially Useful for Cardiovascular Protection? J Am Board Fam Med, November 1, 2009; 22(6): 686 - 697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Hackam Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: Yes Stroke, September 1, 2009; 40(9): 3159 - 3160. [Full Text] [PDF]
|
|
|
|
 |
|
 L. K. Bartholomew, W. C Cushman, J. A Cutler, B. R Davis, G. Dawson, P. T Einhorn, J. F Graumlich, L. B Piller, S. Pressel, E. J Roccella, et al. Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project Clinical Trials, August 1, 2009; 6(4): 329 - 343. [Abstract] [PDF]
|
|
|
|
 |
|
 J. T. Wright Jr, J. L. Probstfield, W. C. Cushman, S. L. Pressel, J. A. Cutler, B. R. Davis, P. T. Einhorn, M. Rahman, P. K. Whelton, C. E. Ford, et al. ALLHAT Findings Revisited in the Context of Subsequent Analyses, Other Trials, and Meta-analyses Arch Intern Med, May 11, 2009; 169(9): 832 - 842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Muntner, M. Krousel-Wood, A. D. Hyre, E. Stanley, W. C. Cushman, J. A. Cutler, L. B. Piller, G. A. Goforth, and P. K. Whelton Antihypertensive Prescriptions for Newly Treated Patients Before and After the Main Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Results and Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Guidelines Hypertension, April 1, 2009; 53(4): 617 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Parra, R. Rosenstein, M. H. Strauss, J. Weinstein, G. E. Newton, B. R. Davis, P. K. Whelton, the ALLHAT Collaborative Research Group, K. A. Jamerson, and M. A. Weber Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension N. Engl. J. Med., March 12, 2009; 360(11): 1147 - 1150. [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Gibbons, D. W. Jones, T. J. Gardner, L. B. Goldstein, J. H. Moller, and C. W. Yancy The American Heart Association's 2008 Statement of Principles for Healthcare Reform Circulation, November 18, 2008; 118(21): 2209 - 2218. [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Wright, Q. Chen, N. L. Baye, Y. Huang, C. L. Healy, S. Kasinathan, and T. D. O'Connell Nuclear {alpha}1-Adrenergic Receptors Signal Activated ERK Localization to Caveolae in Adult Cardiac Myocytes Circ. Res., October 24, 2008; 103(9): 992 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Chapman, C. L. Chang, B. Dahlof, P. S. Sever, H. Wedel, N. R. Poulter, and on behalf of the ASCOT Investigators Effect of Doxazosin Gastrointestinal Therapeutic System as Third-Line Antihypertensive Therapy on Blood Pressure and Lipids in the Anglo-Scandinavian Cardiac Outcomes Trial Circulation, July 1, 2008; 118(1): 42 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Cutler and B. R. Davis Thiazide-Type Diuretics and {beta}-Adrenergic Blockers as First-Line Drug Treatments for Hypertension Circulation, May 20, 2008; 117(20): 2691 - 2705. [Full Text] [PDF]
|
|
|
|
 |
|
 H. R. Black, B. Davis, J. Barzilay, C. Nwachuku, C. Baimbridge, H. Marginean, J. T. Wright Jr., J. Basile, N. D. Wong, P. Whelton, et al. Metabolic and Clinical Outcomes in Nondiabetic Individuals With the Metabolic Syndrome Assigned to Chlorthalidone, Amlodipine, or Lisinopril as Initial Treatment for Hypertension: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Diabetes Care, February 1, 2008; 31(2): 353 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Woodcock, X.-J. Du, M. E. Reichelt, and R. M. Graham Cardiac {alpha}1-adrenergic drive in pathological remodelling Cardiovasc Res, February 1, 2008; 77(3): 452 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Wright Jr, S. Harris-Haywood, S. Pressel, J. Barzilay, C. Baimbridge, C. J. Bareis, J. N. Basile, H. R. Black, R. Dart, A. K. Gupta, et al. Clinical Outcomes by Race in Hypertensive Patients With and Without the Metabolic Syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Arch Intern Med, January 28, 2008; 168(2): 207 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. I. Lynch, E. Boerwinkle, B. R. Davis, C. E. Ford, J. H. Eckfeldt, C. Leiendecker-Foster, and D. K. Arnett Pharmacogenetic Association of the NPPA T2238C Genetic Variant With Cardiovascular Disease Outcomes in Patients With Hypertension JAMA, January 23, 2008; 299(3): 296 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. U. Park and A. L. Taylor Race and Ethnicity in Trials of Antihypertensive Therapy to Prevent Cardiovascular Outcomes: A Systematic Review Ann. Fam. Med, September 1, 2007; 5(5): 444 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-J. Du, X.-M. Gao, H. Kiriazis, X.-L. Moore, Z. Ming, Y. Su, A. M. Finch, R. A. Hannan, A. M. Dart, and R. M. Graham Transgenic {alpha}1A-adrenergic activation limits post-infarct ventricular remodeling and dysfunction and improves survival Cardiovasc Res, September 1, 2006; 71(4): 735 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H.H. Leenen, C. E. Nwachuku, H. R. Black, W. C. Cushman, B. R. Davis, L. M. Simpson, M. H. Alderman, S. A. Atlas, J. N. Basile, A. B. Cuyjet, et al. Clinical Events in High-Risk Hypertensive Patients Randomly Assigned to Calcium Channel Blocker Versus Angiotensin-Converting Enzyme Inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Hypertension, September 1, 2006; 48(3): 374 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Thornley-Brown, X. Wang, J. T. Wright Jr, O. S. Randall, E. R. Miller, J. P. Lash, J. Gassman, G. Contreras, L. J. Appel, L. Y. Agodoa, et al. Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease. Arch Intern Med, April 10, 2006; 166(7): 797 - 805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rahman, S. Pressel, B. R. Davis, C. Nwachuku, J. T. Wright Jr., P. K. Whelton, J. Barzilay, V. Batuman, J. H. Eckfeldt, M. A. Farber, et al. Cardiovascular Outcomes in High-Risk Hypertensive Patients Stratified by Baseline Glomerular Filtration Rate Ann Intern Med, February 7, 2006; 144(3): 172 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rahman, S. Pressel, B. R. Davis, C. Nwachuku, J. T. Wright Jr, P. K. Whelton, J. Barzilay, V. Batuman, J. H. Eckfeldt, M. Farber, et al. Renal Outcomes in High-Risk Hypertensive Patients Treated With an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker vs a Diuretic: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Arch Intern Med, April 25, 2005; 165(8): 936 - 946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Wright Jr, J. K. Dunn, J. A. Cutler, B. R. Davis, W. C. Cushman, C. E. Ford, L. J. Haywood, F. H. H. Leenen, K. L. Margolis, V. Papademetriou, et al. Outcomes in Hypertensive Black and Nonblack Patients Treated With Chlorthalidone, Amlodipine, and Lisinopril JAMA, April 6, 2005; 293(13): 1595 - 1608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Davis, C. D. Furberg, J. T. Wright Jr., J. A. Cutler, P. Whelton, and the ALLHAT Collaborative Research Group ALLHAT: Setting the Record Straight Ann Intern Med, July 6, 2004; 141(1): 39 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Frey, H. A. Katus, E. N. Olson, and J. A. Hill Hypertrophy of the Heart: A New Therapeutic Target? Circulation, April 6, 2004; 109(13): 1580 - 1589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Joles and H. A. Koomans Causes and Consequences of Increased Sympathetic Activity in Renal Disease Hypertension, April 1, 2004; 43(4): 699 - 706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Koomans, P. J. Blankestijn, and J. A. Joles Sympathetic Hyperactivity in Chronic Renal Failure: A Wake-up Call J. Am. Soc. Nephrol., March 1, 2004; 15(3): 524 - 537. [Abstract] [Full Text] [PDF]
|
|